Continuous vancomycin infusion versus intermittent infusion for dose adjustment in patients with under therapeutic drug level

Phase 4

Completed

• Conditions: critically illmethicillin-resistantvancomycin level under therapeutic target; vancomycin; therapeutic drug monitoring; continuous infusion

• Registration Number: TCTR20210122005
• Lead Sponsor: Faculty of Medicine Siriraj Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-22
• Study Completion: 2022-01-30
• Results First Posted: 2022-12-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. Adult patients (18 years old or over)
2. Creatinine clearance (CrCl) by Cockcroft-Gault formula of more than 30 ml/min/1.73m2
3. Had or was suspected of having Staphylococcal or Enterococcal infections
4. Vancomycin was indicated and was anticipated for at least 48 hours.

Exclusion Criteria

1. History of receiving vancomycin within 48 hours before the study
2. History of vancomycin allergy
3. Pregnant or lactating woman
4. Patient with acute kidney injury
5. Body mass index below 15 kg/m2
5. Receiving renal replacement therapy or extracorporeal membrane oxygenator
6. The treating physician considers as inappropriate for continuous infusion.
7. Do-not-resuscitation and terminally ill condition
8. Denials the consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum vancomycin level within the therapeutic target within 48 hours At 48 hours after continuous infusion Serum vancomycin level

Secondary Outcome Measures

Name	Time	Method
Serum vancomycin level within the therapeutic target within 96 hours At 96 hours after continuous infusion Serum vancomycin level,Number of serum vancomycin level tested Before reaching the therapeutic target Number of serum vancomycin level tested,Successful treatment Within the admission Resolution of the infection,Mortality 14 days after continuous infusion and within the admission Mortality at 14 days after continuous infusion and in-hospital mortality,Acute kidney injury 48 hours after discontinuation of continuous vancomycin infusion Absolute increase in serum creatinine at least 0.3 mg/dL or at least 1.5-fold from baseline,Occurrence of adverse drug reaction 48 hours after discontinuation of continuous vancomycin infusion drug induced cytopenia, vancomycin related phlebitis, ototoxicity